Skip to main content
Skip to main content
MNTL logo

Tema Neuroscience And Mental Health ETF (MNTL) Stock Analysis

DELISTED 2025

What happened to Tema Neuroscience And Mental Health ETF (MNTL) stock?

Tema Neuroscience And Mental Health ETF (MNTL) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.

MCap: $10.3M| Vol: 133|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Tema Neuroscience And Mental Health ETF (MNTL) trades at $23.80. The Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed fund focused on companies involved in treating central nervous system and mental… Market cap: $10.3M, Sector: Financial services.

Last analyzed: Mar 17, 2026
The Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed fund focused on companies involved in treating central nervous system and mental health disorders. It seeks to provide long-term capital growth by investing in innovative treatments within this specialized healthcare segment.

Analyst Coverage for MNTL: MNTL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MNTL against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the MNTL film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 47/100 · C

MNTL: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Jim Simons
Neutral
Izzy Englander
Bullish
Seth Klarman
Neutral
Moon AI
Bearish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Tema Neuroscience And Mental Health ETF (MNTL) Financial Services Profile

IPO Year2024

Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed fund targeting companies developing treatments for central nervous system and mental health disorders. The fund aims to capitalize on innovation within this specialized healthcare sector, offering investors exposure to companies focused on addressing these critical medical needs.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for MNTL?

As of Mar 17, 2026 — figures reflect the data available on that date.

The Tema Neuroscience and Mental Health ETF (MNTL) presents a targeted investment opportunity within the high-growth area of neurological and psychiatric disorder treatments. With an aging global population and increasing awareness of mental health issues, the demand for innovative therapies is expected to rise. MNTL's actively managed approach allows it to capitalize on emerging trends and promising companies within this space. Key value drivers include the successful development and commercialization of novel treatments, positive clinical trial results, and strategic partnerships. The fund's focus on a specific niche allows for specialized expertise and potentially higher returns compared to broader healthcare ETFs. However, potential risks include regulatory hurdles, clinical trial failures, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

MNTL Key Highlights

MNTL is an actively managed ETF focused on neuroscience and mental health.

  • The fund targets companies involved in the treatment of central nervous system diseases.
  • MNTL aims for long-term capital growth through investments in innovative therapies.
  • The ETF provides exposure to a specialized niche within the healthcare sector.
  • MNTL's market capitalization is $0.01 billion.

Who Are MNTL's Competitors?

MNTL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
DYNI IDX Dynamic Innovation ETF $26.28 +0.11% $10.3M
MJO MicroSectors Cannabis 2X Leveraged ETNs $81.16 +0.00% $15.8M
ALTEX Firsthand Alternative Energy Fund $13.18 -0.98% $9.15M 82
IDKFF ThreeD Capital Inc. $0.07 +17.96% $6.75M 70
BCG Binah Capital Group, Inc. $1.39 -7.33% $23.4M 78
EEA The European Equity Fund, Inc. $11.22 +0.46% $75.2M 67
HNNA Hennessy Advisors, Inc. $10.02 -0.28% $79.2M 81
ETHT ProShares - Ultra Ether ETF $12.57 +19.94% $92.2M 68

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MNTL's Key Strengths?

Specialized focus on a high-growth sector.

  • Active management allows for strategic investment decisions.
  • Potential for high returns due to innovation in the sector.
  • Addresses a critical and growing healthcare need.

What Are MNTL's Weaknesses?

Concentrated investment focus may increase volatility.

  • Reliance on the success of clinical trials and regulatory approvals.
  • Higher management fees compared to passive ETFs.
  • Smaller market capitalization compared to established ETFs.

What Could Drive MNTL Stock Higher?

Positive clinical trial results for portfolio companies.

  • Regulatory approvals for new treatments.
  • Increasing investment in neuroscience research.
  • Growing awareness of mental health issues.

What Are the Key Risks for MNTL?

Clinical trial failures can significantly impact portfolio companies.

  • Regulatory delays or rejections of new treatments.
  • Competition from established pharmaceutical companies with greater resources.
  • Economic downturns may reduce investment in healthcare and impact fund performance.

What Are the Growth Opportunities for MNTL?

  • Increased Investment in Neuroscience Research: The growing recognition of neurological and mental health disorders as significant public health challenges is driving increased investment in research and development. This influx of capital is fueling innovation and creating opportunities for companies developing novel therapies and diagnostic tools. MNTL is positioned to benefit from this trend by investing in companies that are at the forefront of neuroscience research, potentially leading to significant growth in the fund's value as these companies advance their pipelines and bring new products to market.
  • Aging Global Population: The global population is aging, leading to a higher prevalence of age-related neurological disorders such as Alzheimer's disease and Parkinson's disease. This demographic shift is creating a growing demand for effective treatments and care solutions. MNTL can capitalize on this trend by investing in companies that are developing therapies and technologies to address the needs of this aging population, potentially generating significant returns as these companies capture a larger share of the market.
  • Rising Awareness of Mental Health Issues: There is a growing awareness of mental health issues, leading to increased demand for mental health services and treatments. This trend is being driven by factors such as reduced stigma, increased access to information, and greater recognition of the impact of mental health on overall well-being. MNTL can benefit from this trend by investing in companies that are developing innovative therapies and technologies to address mental health disorders, potentially generating significant returns as these companies expand their reach and impact.
  • Technological Advancements in Brain Imaging and Diagnostics: Advancements in brain imaging and diagnostic technologies are enabling earlier and more accurate detection of neurological and mental health disorders. This is leading to improved treatment outcomes and a greater demand for specialized therapies. MNTL can capitalize on this trend by investing in companies that are developing and commercializing these advanced technologies, potentially generating significant returns as these companies become essential tools for healthcare providers.
  • Expansion into Emerging Markets: Emerging markets are experiencing rapid economic growth and urbanization, leading to increased exposure to environmental and lifestyle factors that can contribute to neurological and mental health disorders. This is creating a growing demand for treatments and services in these markets. MNTL can expand its reach by investing in companies that are targeting these emerging markets, potentially generating significant returns as these companies tap into new sources of growth and revenue.

What Are MNTL's Competitive Advantages?

  • Specialized Focus: MNTL's focus on neuroscience and mental health provides a differentiated offering compared to broader healthcare ETFs.
  • Active Management: The fund's active management allows for strategic allocation of capital to promising companies and emerging trends.
  • Expertise: MNTL's management team possesses specialized knowledge of the neuroscience and mental health sector.
  • First-Mover Advantage: As one of the first ETFs to focus on this specific niche, MNTL has established a strong brand and reputation.

What Does MNTL Do?

The Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed exchange-traded fund designed to provide investors with exposure to companies at the forefront of treating diseases affecting the central nervous system (CNS) and mental health. Launched with the objective of long-term capital appreciation, MNTL invests in companies that are actively involved in the research, development, and commercialization of innovative therapies and technologies aimed at addressing a wide range of neurological and psychiatric disorders. This includes companies working on treatments for conditions such as Alzheimer's disease, Parkinson's disease, depression, anxiety, schizophrenia, and other related ailments. By focusing on this specific niche within the healthcare sector, MNTL seeks to capitalize on the growing demand for effective treatments and the increasing investment in neuroscience research. The fund's active management approach allows for strategic allocation of capital to companies with the most promising pipelines and technologies, while also considering factors such as market potential, regulatory landscape, and competitive dynamics. MNTL aims to provide investors with a diversified portfolio of companies that are driving innovation in the field of neuroscience and mental health, offering a unique investment opportunity within the broader healthcare market.

What Products and Services Does MNTL Offer?

  • Invests in companies focused on treating diseases of the central nervous system.
  • Targets companies involved in the research and development of mental health treatments.
  • Provides investors with exposure to the neuroscience and mental health sector.
  • Actively manages a portfolio of companies within this specialized healthcare area.
  • Seeks long-term capital appreciation through strategic investments.
  • Capitalizes on innovation in treatments for CNS diseases.

How Does MNTL Make Money?

  • Actively manages a portfolio of stocks in the neuroscience and mental health sector.
  • Generates revenue through management fees charged to investors.
  • Aims to outperform benchmark indices by strategically selecting investments.
  • Focuses on companies with strong growth potential in the treatment of CNS diseases.

What Industry Does MNTL Operate In?

The asset management industry is characterized by intense competition and evolving investor preferences. ETFs like MNTL compete with traditional mutual funds and other specialized investment vehicles. The neuroscience and mental health sector is experiencing significant growth due to increasing prevalence of neurological disorders and rising awareness of mental health issues. This creates a favorable backdrop for MNTL, as it focuses on companies developing innovative treatments in this space. Competitors include ETFs with broader healthcare mandates, but MNTL's niche focus provides a differentiated offering.

Who Are MNTL's Key Customers?

  • Individual investors seeking exposure to the neuroscience and mental health sector.
  • Institutional investors looking for specialized investment opportunities.
  • Financial advisors seeking to diversify client portfolios.
  • Retirement funds interested in long-term capital appreciation.
AI Confidence: 69% Updated: Mar 17, 2026
ROE 0%

Key Financial Metrics

Return on equity for Tema Neuroscience And Mental Health ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. MNTL trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

How Tema Neuroscience And Mental Health ETF Is Valued

Tema Neuroscience And Mental Health ETF carries a market capitalization of $10.3M, placing it in the micro-cap category.

MNTL Financials

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in MNTL's long-term growth potential, indicating that those closest to the company believe in its future.
  • Community sentiment has shifted positively, with discussions highlighting the increasing focus on mental health and neuroscience, making MNTL relevant in today's market.
  • The ETF's diversified approach may attract investors looking for stability in a volatile market, as mental health continues to gain traction as a critical issue.
  • Recent media coverage has spotlighted mental health awareness, potentially driving more interest and investment into funds like MNTL.

Bear Case

  • Some analysts express caution due to the competitive landscape in the ETF space, where many funds are vying for investor attention and capital.
  • Community discussions reveal concerns about the ETF's performance relative to broader market trends, with some feeling it may lag behind more established sectors.
  • There are worries regarding the sustainability of the mental health narrative, as market fads can fade quickly, impacting investor sentiment negatively.
  • Recent market volatility has led to skepticism about thematic ETFs like MNTL, with some investors preferring traditional sectors for perceived safety.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

MNTL Latest News

No recent news available for MNTL.

What Investors Ask About Tema Neuroscience And Mental Health ETF (MNTL) — Financial Services

What happened to Tema Neuroscience And Mental Health ETF (MNTL) stock?

Tema Neuroscience And Mental Health ETF (MNTL) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.

Can I still buy MNTL shares?

No. MNTL stopped trading on public markets in August 2025, so the shares are not available through a broker. Anything you see quoted for MNTL elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before MNTL stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to Tema Neuroscience And Mental Health ETF. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

What does Tema Neuroscience And Mental Health ETF do?

The Tema Neuroscience and Mental Health ETF (MNTL) is an actively managed fund that invests in companies involved in the research, development, and commercialization of treatments for diseases affecting the central nervous system and mental health. The fund aims to provide long-term capital growth by capitalizing on innovation in this specialized healthcare sector.

What are the main risks for MNTL?

The main risks for MNTL include the inherent volatility of the healthcare sector, particularly the biotechnology and pharmaceutical industries. Clinical trial failures and regulatory setbacks for portfolio companies can significantly impact the fund's performance. Additionally, competition from established pharmaceutical companies with greater resources poses a challenge. Economic downturns may also reduce investment in healthcare, affecting the fund's overall value.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • AI analysis pending for MNTL, limiting comprehensive insights.
  • Financial data based on limited information.
Data Sources

Popular Stocks

More Stocks We Cover